JNJ ‘was never dependent on COVID vaccine’ for success: CFO Wolk

October 17, 2023 07:15 AM PDT | By Invezz

JNJ ‘was never dependent on COVID vaccine’ for success: CFO Wolk — Image source: Invezz

JNJ stock up on improved outlook

The stock is being rewarded also because the management raised its guidance for the full year on Tuesday.

Johnson & Johnson is now calling for $10.07 to $10.13 of adjusted per-share earnings for fiscal 2023. On CNBC’s “Squawk Box”, Joseph Wolk – its Chief Financial Officer said:

The quarter was strong. We’re even more encouraged about the future. We’ve got great data readouts happening as early as this week at the European Society for Medical Oncology.

The finance chief also confirmed that he would have raised the guidance further if it wasn’t for currency headwinds. JNJ shares are down over 10% for the year at writing.

johnson & johnson q3 earnings release — jnj product

Johnson & Johnson recently separated Kenvue

The earnings release arrives only a couple months after Johnson & Johnson separated its consumer health business that now trades on the New York Stock Exchange as Kenvue. That separation raised $13.2 billion for the multinational in cash proceeds.

Note that JNJ still has a 9.5% stake in Kenvue. According to CFO Wolk:

It’s a good investment. It provides us flexibility to raise cash, lean into our capital allocation priorities, doing a deal, or simply raising the dividend as we have for 61 consecutive years.

Johnson & Johnson currently pays a dividend yield of 3.01%. Wall Street currently has a consensus “overweight” rating on this pharmaceutical and medtech stock.

$JNJ Johnson & Johnson beat on top and bottom line with Q3 Medical Device organic growth +10% YoY led by Interventional Solutions (cardiology programs) that beat expectations for 2nd consecutive quarter. Not too shabby considering overblown market concerns about GLP-1 threat. pic.twitter.com/4Q7ylPAG7m

— JaguarAnalytics (@JaguarAnalytics) October 17, 2023

Notable figures in JNJ Q3 earnings release

Earned $4.309 billion versus the year-ago $4.310 billion
Per-share earnings climbed from $1.62 to $1.69
Adjusted EPS printed at $2.66 as per the press release
Sales jumped 6.8% year-on-year to $21.35 billion
Consensus was $2.52 a share on $21.036 billion sales

JNJ said both innovative medicine and medtech segments contributed to strength in the recently concluded quarter. The former was up 5.1% while the latter popped 10% in Q3.

CFO Wolk agreed that COVID vaccine sales were minimal at this point but said:

Our financial performance and success was never dependent on the COVID-19 vaccine. We are very well-positioned not just for the balance of this year but into 2024 and beyond.

Watch here: https://www.youtube.com/embed/2rLmcfROkok?feature=oembed

The post JNJ ‘was never dependent on COVID vaccine’ for success: CFO Wolk appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.